Golimumab in the treatment of psoriatic arthritis.

Authors: Love TJ, Kavanaugh A Abstract INTRODUCTION: Psoriatic arthritis is an inflammatory arthritis that can be aggressive and destructive, resulting in significant morbidity. While many new agents have been approved for the treatment of psoriatic arthritis over the past decade, TNF inhibitors remain an anchor treatment, in part based on extensive clinical experience. Recently, the TNF inhibitor golimumab was approved for intravenous use in psoriatic arthritis. Areas covered: This expert review presents an overview of the currently available treatment options for psoriatic arthritis with a focus on the evidence from clinical trials supporting the use of golimumab in psoriatic arthritis. This information is placed in context with recent advances in the understanding of psoriatic a...

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2NUAOfj